Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer.
Hori N, Iwasa S, Hashimoto H, Yanai T, Kato K, Hamaguchi T, Yamada Y, Murakoshi K, Yokote N, Yamamoto H, Shimada Y.
Hori N, et al. Among authors: yamamoto h.
Int J Clin Oncol. 2013 Jun;18(3):435-8. doi: 10.1007/s10147-012-0398-4. Epub 2012 Mar 14.
Int J Clin Oncol. 2013.
PMID: 22415742